ReviewIntegrated blood pressure control2020
Matrix Metalloproteinases and Hypertension-Mediated Organ Damage: Current Insights.
Review in Integrated blood pressure control, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Assessing Sarcocornia as a Salt Substitute: Effects on Lipid Profile and Gelatinase Activity.Nutrients · 2024Trial
- Neurohumoral Biomarker Profile Associated With Blood Pressure Response After Renal Denervation.Journal of clinical hypertension (Greenwich, Conn.) · 2026Article
- Effects of antihypertensive therapy on matrix metalloproteinase-9 levels in controlled hypertensive patients.BMC cardiovascular disorders · 2026Article
- Sex-Specific Exosome Cargo Reveals Potential New Mechanisms of Salt-Sensitive Hypertension.Hypertension (Dallas, Tex. : 1979) · 2026Article
- HIIT versus MICT on Blood Pressure and Cardiac Biomarkers in L-NAME-induced Hypertensive Rats.International journal of exercise science · 2026Article
- Matrix metalloproteinase-2 (PeerJ · 2026Article
- The effects of purslane consumption on blood pressure in adults: A grading of recommendations, assessment, development, and evaluation-assessed systematic review and meta-analysis of randomized controlled trials.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2025Review
- Association Between rs243866 Polymorphism of the MMP-2 Gene and Target Organ Damage in Patients with Uncontrolled Hypertension.Acta informatica medica : AIM : journal of the Society for Medical Informatics of Bosnia & Herzegovina : casopis Drustva za medicinsku informatiku BiH · 2025Article
- Endothelial Function Biomarkers in Hypertension.Current medicinal chemistry · 2025Review
- Article
- Review
- Plasma Biomarkers for Hypertension-Mediated Organ Damage Detection: A Narrative Review.Biomedicines · 2024Review
- Prognostic utility of rhythmic components in 24-h ambulatory blood pressure monitoring for the risk stratification of chronic kidney disease patients with cardiovascular co-morbidity.Journal of human hypertension · 2024Article
- Association of Body Mass Index with Matrix Metalloproteinase-9, Tissue Inhibitor of Metalloproteinase-1, and Interleukin-6 Based on Blood Pressure.Reports of biochemistry & molecular biology · 2024Article
- Arterial hypertension in the chronic evolution of migraine: bystander or risk factor? An overview.The journal of headache and pain · 2024Review
- Matrix Metalloproteinases in Cardioembolic Stroke: From Background to Complications.International journal of molecular sciences · 2023Review
- Responses Triggered by the Immune System in Hypertensive Conditions and Repercussions on Target Organ Damage: A Review.Current cardiology reviews · 2023Review
- Article
- The effects of alpha lipoic acid (ALA) supplementation on blood pressure in adults: a GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials.Frontiers in cardiovascular medicine · 2023Review
- TIMP-1 in the prognosis of patients who underwent coronary artery bypass surgery: a 12-year follow-up study.Frontiers in cardiovascular medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Matrix metalloproteinases (MMPs) are important extracellular enzymes involved in many physiological and pathological processes. Changes in the activity and concentration of specific MMPs, as well as the unbalance with their inhibitors (tissue inhibitors of metalloproteinases - TIMPs), have been described as a part of the pathogenic cascade promoted by arterial hypertension. MMPs are able to degrade various protein substrates in the extracellular matrix, to influence endothelial cells function, vascular smooth muscle cells migration, proliferation and contraction, and to stimulate cardiomyocytes changes. All these processes can be activated by chronically elevated blood pressure values. Animal and human studies demonstrated the key function of MMPs in the pathogenesis of hypertension-mediated vascular, cardiac, and renal damage, besides age and blood pressure values. Thus, the role of MMPs as biomarkers of hypertension-mediated organ damage and potential pharmacological treatment targets to prevent further cardiovascular and renal complications in hypertensive population is increasingly supported. In this review, we aimed to describe the main scientific evidence about the behavior of MMPs in the development of vascular, cardiac, and renal damage in hypertensive patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.